Cyclosporin A efficacy and toxicity in organ transplantation with special focus on cadaveric renal transplantation.
The pharmacodynamic and pharmacokinetic properties of cyclosporin A are reviewed. Its adverse reactions and posology in allograft transplantation are described according to clinical experience. Preliminary results with the use of cyclosporin A (Cy A) in primary cadaveric renal transplant patients, in comparison to 3 other conventional treatments, are reported in a randomized study of 69 patients: even if graft acute tubular necrosis is more frequent in the Cy A group, this group is the one which reaches the most successful short term renal graft survival.